

Medication	Comments
Multi Source Brand Medications	N/A

OVERRIDE(S)

Prior Authorization of Benefits

APPROVAL DURATION

1 Year

APPROVAL CRITERIA

Brands with a generic available may be approved for the following:

- I. The patient has failed an adequate trial of a chemically equivalent generic agent, by 2 different manufacturers (when available by at least 2 manufacturers) **AND**
 - A. Generics have inadequate response; **OR**
 - B. Generics caused adverse outcome; **OR**
 - C. The patient has a genuine allergic reaction to an **inactive** ingredient in generic agent(s). Allergic reaction(s) must be clearly documented in the patient's medical record.

Note: GI upset or irritation is not generally considered an allergy or failed treatment. Patients should be referred to their physician or pharmacist for advice on dose adjustment, and/or other options to reduce GI upset/irritation. Common documented side effects attributed to the drug (i.e. headache, nausea, blurred vision, fatigue, muscle aches) are not considered an allergy and would be expected to occur at the same level in both the generic and brand agent.

Drugs Excluded from the Multisource Brand Initiative (including NTI drugs)	
Armour Thyroid	Neoral
Banzel	Pancrease
Carbatrol	Pancrease
CellCept	Pancrecarb
Celontin	Pancrelipase
Clozaril	Peganone
Cordarone	Phenytek
Coumadin	Prograf
Creon	Sabril
Depacon	Sandimmune
Depakene	Stavzor
Depakote	Synthroid
Depakote ER	Tegretol
Diastat	Tegretol XR
Dilantin	Theophylline Products

Eskalith	Tirosint
Eskalith CR	Topamax
Felbatol	Topamax Sprinkle
Gabitril	Tri-Pase
Keppra	Trileptal
Keppra XR	Ultrase
Lamictal (all forms)	Vimpat
Lanoxin	Viokase
Lithobid	Zarontin
Myfortic	Zenpep
Mysoline	Zonegran